Division of Medical Microbiology, Department of Laboratory Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University and National Health Laboratory Services, Mthatha, Eastern Cape, South Africa.
Department of Biological and Environmental Sciences, Walter Sisulu University, Mthatha, Eastern Cape, South Africa.
Sci Rep. 2021 Mar 29;11(1):7110. doi: 10.1038/s41598-021-86570-y.
The proliferation of extended spectrum beta-lactamase (ESBL) producing Pseudomonas aeruginosa represent a major public health threat. In this study, we evaluated the antimicrobial resistance patterns of P. aeruginosa strains and characterized the ESBLs and Metallo- β-lactamases (MBL) produced. Strains of P. aeruginosa cultured from patients who attended Nelson Mandela Academic Hospital and other clinics in the four district municipalities of the Eastern Cape between August 2017 and May 2019 were identified; antimicrobial susceptibility testing was carried out against thirteen clinically relevant antibiotics using the BioMérieux VITEK 2 and confirmed by Beckman autoSCAN-4 System. Real-time PCR was done using Roche Light Cycler 2.0 to detect the presence of ESBLs; bla, bla and bla genes; and MBLs; bla, bla Strains of P. aeruginosa demonstrated resistance to wide-ranging clinically relevant antibiotics including piperacillin (64.2%), followed by aztreonam (57.8%), cefepime (51.5%), ceftazidime (51.0%), piperacillin/tazobactam (50.5%), and imipenem (46.6%). A total of 75 (36.8%) multidrug-resistant (MDR) strains were observed of the total pool of isolates. The bla, bla and bla was detected in 79.3%, 69.5% and 31.7% isolates (n = 82), respectively. The bla was detected in 1.25% while no bla was detected in any of the strains tested. The study showed a high rate of MDR P. aeruginosa in our setting. The vast majority of these resistant strains carried bla and bla genes. Continuous monitoring of antimicrobial resistance and strict compliance towards infection prevention and control practices are the best defence against spread of MDR P. aeruginosa.
产超广谱β-内酰胺酶(ESBL)的铜绿假单胞菌的增殖对公共健康构成了重大威胁。在本研究中,我们评估了铜绿假单胞菌菌株的抗菌药物耐药模式,并对产生的 ESBL 和金属β-内酰胺酶(MBL)进行了特征描述。从 2017 年 8 月至 2019 年 5 月期间,在纳尔逊·曼德拉学术医院和东开普省四个地区医疗中心的患者中培养的铜绿假单胞菌菌株进行鉴定;使用生物梅里埃 VITEK 2 对 13 种临床相关抗生素进行药敏试验,并通过贝克曼 autoSCAN-4 系统进行确认。使用罗氏 Light Cycler 2.0 进行实时 PCR 检测 ESBLs;bla、bla 和 bla 基因;以及 MBLs;bla、bla 铜绿假单胞菌菌株对包括哌拉西林(64.2%)在内的广泛临床相关抗生素具有耐药性,其次是氨曲南(57.8%)、头孢吡肟(51.5%)、头孢他啶(51.0%)、哌拉西林/他唑巴坦(50.5%)和亚胺培南(46.6%)。在所检测的分离株中,共有 75 株(36.8%)为多重耐药(MDR)菌株。bla、bla 和 bla 分别在 79.3%、69.5%和 31.7%的分离株(n=82)中检测到。在 1.25%的菌株中检测到 bla,而在任何检测的菌株中均未检测到 bla。研究表明,在我们的环境中存在很高比例的 MDR 铜绿假单胞菌。这些耐药菌株绝大多数携带 bla 和 bla 基因。持续监测抗菌药物耐药性,并严格遵守感染预防和控制措施,是防止 MDR 铜绿假单胞菌传播的最佳防御措施。